Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Sep 6–Sep 13, 2026)

· 1 min read

This week’s biotech calendar is unusually quiet on the regulatory and earnings fronts, with no PDUFA dates or earnings reports scheduled. The lone catalyst worth watching is the SIGN study evaluating communicable disease assessment protocols for migrants in reception centers, a public health-focused readout rather than a commercial one. Expect thin newsflow and low volatility across the sector this week.

🧪 Trial Catalysts & Milestones

  • SIGN — 2026-09-08: Evaluation and Assessment for Communicable Diseases in Migrants Hosted in Reception Center

📡 Run-up Radar Highlights

Stocks entering the pre-catalyst window with the strongest setups (full radar is a Premium feature):

  • OSTX — Phase 1 — Recruiting in 10 days, score 67/100
  • NUVL — NDA in 12 days, score 61/100
  • MIRM — NDA in 20 days, score 54/100

📈 Last Week’s Biggest Gainers

  • FRVO +28.41% (volume 11.1x average)
  • EGIEY +17.80% (volume 0.0x average)
  • MSTR +17.56% (volume 1.9x average)
  • SMMT +17.33% (volume 2.9x average)
  • HCM +17.19% (volume 9.2x average)

Track your tickers on the BioRadar dashboard →

This digest is for informational purposes only and is not investment advice. Always do your own research.

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.